partnering

News

Sanofi backs out of $500m cancer alliance with Revolution

Sanofi has walked away from a four-year-old partnership with Revolution Medicines focused on an SHP2 inhibitor, intended as a combination with KRAS inhibitors, including Sanofi’s Mirati-par

News

GSK's pullback from cell therapy continues as Immatics allia...

Immatics has become the latest partner for GSK in the area of cell therapy for cancer to see its alliance shelved, just two and a half years after being set up.

News

Roche deepens ties with Jnana with a second licensing deal

Swiss pharma group Roche has doubled down on a partnership with Jnana Therapeutics, paying $50 million upfront to tap into the Boston-based biotech drug discovery platform for a wide-rangin

News

Lantheus on POINT in radio-oncology with $2bn licensing deal

Lantheus' pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma.

News

Merck teams up with Synthekine in $525m cytokine partnership

Merck & Co has made another move towards diversifying its pipeline and reducing its reliance on blockbuster cancer drug Keytruda, pledging $525 million to an alliance with Synthekine in

News

Sanofi signs $1.2bn research alliance with AI specialist Ins...

Sanofi has tapped into the artificial intelligence expertise of Chinese biotech Insilico Medicine with a six-compound drug discovery collaboration that could be worth up to $1.2 billion.

Sanofi backs out of $500m cancer alliance with Revolution

GSK's pullback from cell therapy continues as Immatics allia...

Roche deepens ties with Jnana with a second licensing deal

Lantheus on POINT in radio-oncology with $2bn licensing deal

Merck teams up with Synthekine in $525m cytokine partnership

Sanofi signs $1.2bn research alliance with AI specialist Ins...

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

partnering

Editor's Picks